Shape Our Content: Take The Reader Survey

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

woman filling in satisfaction engagement survey on laptop
• Source: Shutterstock: Munthita

We value your feedback and suggestions as we look to improve the format of our content and the way it is delivered to you. By completing our customer survey, you can provide your input on essential aspects of content and delivery.

The survey asks about your preferred content formats, such as articles, infographics, podcasts, data trackers and videos; how you access our content, e.g. email, website, PDF, mobile app and RSS; and coverage areas you value or would like to see more of.

We also want to hear about the accessibility and ease of use of our content, as well as your thoughts about features such as AI, audio articles and article translation. The survey results will help us decide what changes to format, delivery, product features and content coverage will be most valuable to you.

The survey should only take seven minutes to complete, and you get the chance to win an Amazon gift voucher just by taking part. The deadline for survey responses is 17 September.

Take the survey

To discuss the editorial content of In Vivo at any time, reach out to me at eleanor.malone@citeline.com.

More from Archive

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By 

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.